Note the timing if you notice it
Retatrutide is an investigational once-weekly injectable triple receptor agonist that simultaneously activates GLP-1, GIP, and glucagon receptors to reduce appetite, enhance insulin secretion, and potentially increase energy expenditure
GLP-1 is an incretin hormone secreted by the intestine after food intake
Monitoring and follow-up should continue as recommended for tirzepatide therapy, typically including assessment of glycemic control (A1C), weight, gastrointestinal tolerability, and screening for potential adverse effects
Safety Information, Contraindications, and Side Effects The following is drawn directly from Eden's official safety information page
Members can attend in-person or online meetings for community accountability and receive support from community coaches